{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:35:21Z","timestamp":1791315321101,"version":"4.3.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,6]]},"DOI":"10.7759\/cureus.85448","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T07:37:41Z","timestamp":1749195461000},"source":"Crossref","is-referenced-by-count":2,"title":["Clinical Assessment of Abrocitinib, Tofacitinib, and Cyclosporine in Adult Patients With Moderate to Severe Atopic Dermatitis: A Retrospective Analysis"],"prefix":"10.7759","author":[{"given":"Shahnawaz","family":"Bashir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1361005","article-title":"Unraveling the skin; a comprehensive review of atopic dermatitis, current understanding, and approaches","volume":"15","author":"Afshari M","year":"2024","unstructured":"Afshari M, Kolackova M, Rosecka M, \u010celakovsk\u00e1 J, Krejsek J. Unraveling the skin; a comprehensive review of atopic dermatitis, current understanding, and approaches. Front Immunol. 2024, 15:1361005. 10.3389\/fimmu.2024.1361005","journal-title":"Front Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v105.40704","article-title":"Evaluating the real-world effectiveness of systemic treatments in atopic dermatitis using the atopic dermatitis control tool (ADCT): a multi-centre, prospective study","volume":"105","author":"Lee HJ","year":"2025","unstructured":"Lee HJ, Woo Y, Lee YB, Lee JH, Kim JE, Lee JH, Cho SH. Evaluating the real-world effectiveness of systemic treatments in atopic dermatitis using the atopic dermatitis control tool (ADCT): a multi-centre, prospective study. Acta Derm Venereol. 2025, 105:40704. 10.2340\/actadv.v105.40704","journal-title":"Acta Derm Venereol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.06.044","article-title":"Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection","volume":"8","author":"Fishbein AB","year":"2020","unstructured":"Fishbein AB, Silverberg JI, Wilson EJ, Ong PY. Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection. J Allergy Clin Immunol Pract. 2020, 8:91-101. 10.1016\/j.jaip.2019.06.044","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0284-y","article-title":"Discordance between physician- and patient-reported disease severity in adults with atopic dermatitis: a US cross-sectional survey","volume":"18","author":"Wei W","year":"2017","unstructured":"Wei W, Anderson P, Gadkari A, et al.. Discordance between physician- and patient-reported disease severity in adults with atopic dermatitis: a US cross-sectional survey. Am J Clin Dermatol. 2017, 18:825-35. 10.1007\/s40257-017-0284-y","journal-title":"Am J Clin Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.07.043","article-title":"The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials","volume":"134","author":"Schmitt J","year":"2014","unstructured":"Schmitt J, Spuls PI, Thomas KS, et al.. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol. 2014, 134:800-7. 10.1016\/j.jaci.2014.07.043","journal-title":"J Allergy Clin Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1699516","article-title":"Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT)","volume":"36","author":"Pariser DM","year":"2020","unstructured":"Pariser DM, Simpson EL, Gadkari A, et al.. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Curr Med Res Opin. 2020, 36:367-76. 10.1080\/03007995.2019.1699516","journal-title":"Curr Med Res Opin"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.12314","article-title":"Clinical approach to patients with moderate-to-severe atopic dermatitis: a Spanish Delphi consensus","volume":"103","author":"Pereyra-Rodriguez JJ","year":"2023","unstructured":"Pereyra-Rodriguez JJ, Baldrich ES, Ruiz-Villaverde R, et al.. Clinical approach to patients with moderate-to-severe atopic dermatitis: a Spanish Delphi consensus. Acta Derm Venereol. 2023, 103:12314. 10.2340\/actadv.v103.12314","journal-title":"Acta Derm Venereol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14891","article-title":"Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I","volume":"32","author":"Wollenberg A","year":"2018","unstructured":"Wollenberg A, Barbarot S, Bieber T, et al.. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018, 32:657-82. 10.1111\/jdv.14891","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2019.31.6.654","article-title":"2019 consensus Korean diagnostic guidelines to define severity classification and treatment refractoriness for atopic dermatitis: objective and subjective assessment of severity","volume":"31","author":"Kim JE","year":"2019","unstructured":"Kim JE, Shin MK, Park GH, et al.. 2019 consensus Korean diagnostic guidelines to define severity classification and treatment refractoriness for atopic dermatitis: objective and subjective assessment of severity. Ann Dermatol. 2019, 31:654-61. 10.5021\/ad.2019.31.6.654","journal-title":"Ann Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16527","article-title":"English version of clinical practice guidelines for the management of atopic dermatitis 2021","volume":"49","author":"Saeki H","year":"2022","unstructured":"Saeki H, Ohya Y, Furuta J, et al.. English version of clinical practice guidelines for the management of atopic dermatitis 2021. J Dermatol. 2022, 49:e315-75. 10.1111\/1346-8138.16527","journal-title":"J Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.08.103","article-title":"Executive summary: guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies","volume":"90","author":"Davis DM","year":"2024","unstructured":"Davis DM, Drucker AM, Alikhan A, et al.. Executive summary: guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024, 90:342-5. 10.1016\/j.jaad.2023.08.103","journal-title":"J Am Acad Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.ijd_843_22","article-title":"Real-world efficacy and safety of oral tofacitinib in patients with refractory moderate to severe atopic dermatitis: a multicenter retrospective study","volume":"69","author":"Dhar S","year":"2024","unstructured":"Dhar S, De A, Sarda A, Godse K, Lahiri K. Real-world efficacy and safety of oral tofacitinib in patients with refractory moderate to severe atopic dermatitis: a multicenter retrospective study. Indian J Dermatol. 2024, 69:292-5. 10.4103\/ijd.ijd_843_22","journal-title":"Indian J Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431X2024e13392","article-title":"A real-world disproportionality analysis of cyclosporine from the FDA Adverse Event Reporting System (FAERS) database","volume":"57","author":"Cui S","year":"2024","unstructured":"Cui S, Li L, Liu W, Zhao B, Zhong X. A real-world disproportionality analysis of cyclosporine from the FDA Adverse Event Reporting System (FAERS) database. Braz J Med Biol Res. 2024, 57:13392. 10.1590\/1414-431X2024e13392","journal-title":"Braz J Med Biol Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.idoj_449_24","article-title":"Abrocitinib: a comprehensive review of its efficacy and safety in dermatology","volume":"15","author":"Dogra S","year":"2024","unstructured":"Dogra S, Shah S, Gupta M, Sharma A, Chhabra S. Abrocitinib: a comprehensive review of its efficacy and safety in dermatology. Indian Dermatol Online J. 2024, 15:930-41. 10.4103\/idoj.idoj_449_24","journal-title":"Indian Dermatol Online J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0625.2001.100102.x","article-title":"The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group","volume":"10","author":"Hanifin JM","year":"2001","unstructured":"Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001, 10:11-8. 10.1034\/j.1600-0625.2001.100102.x","journal-title":"Exp Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.25259\/IJSA_50_2024","article-title":"Assessing eczema severity: a comprehensive review of scoring systems","volume":"4","author":"Suresh S","year":"2025","unstructured":"Suresh S, Kaliyadan F. Assessing eczema severity: a comprehensive review of scoring systems. Indian J Skin Allergy. 2025, 4:19-24. 10.25259\/IJSA_50_2024","journal-title":"Indian J Skin Allergy"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.01.011","article-title":"The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies","volume":"139","author":"Brunner PM","year":"2017","unstructured":"Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017, 139:65-76. 10.1016\/j.jaci.2017.01.011","journal-title":"J Allergy Clin Immunol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz DM","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017, 17:78. 10.1038\/nrd.2017.267","journal-title":"Nat Rev Drug Discov"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson EL","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, et al.. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020, 396:255-66. 10.1016\/S0140-6736(20)30732-7","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04635.x","article-title":"Guidelines for treatment of atopic eczema (atopic dermatitis) part I","volume":"26","author":"Ring J","year":"2012","unstructured":"Ring J, Alomar A, Bieber T, et al.. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012, 26:1045-60. 10.1111\/j.1468-3083.2012.04635.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.07.008","article-title":"Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation","volume":"132","author":"Schmitt J","year":"2013","unstructured":"Schmitt J, Langan S, Deckert S, Svensson A, von Kobyletzki L, Thomas K, Spuls P. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol. 2013, 132:1337-47. 10.1016\/j.jaci.2013.07.008","journal-title":"J Allergy Clin Immunol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.07.042","article-title":"Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults","volume":"121","author":"Silverberg JI","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, et al.. Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults. Ann Allergy Asthma Immunol. 2018, 121:604-612.e3. 10.1016\/j.anai.2018.07.042","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v104.19454","article-title":"Real-world experience of Abrocitinib treatment in patients with atopic dermatitis and hand eczema: up to 28-week results from the BioDay Registry","volume":"104","author":"Kamphuis E","year":"2024","unstructured":"Kamphuis E, Boesjes CM, Loman L, et al.. Real-world experience of Abrocitinib treatment in patients with atopic dermatitis and hand eczema: up to 28-week results from the BioDay Registry. Acta Derm Venereol. 2024, 104:19454. 10.2340\/actadv.v104.19454","journal-title":"Acta Derm Venereol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen LK","year":"2017","unstructured":"Oetjen LK, Mack MR, Feng J, et al.. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017, 171:217-228.e13. 10.1016\/j.cell.2017.08.006","journal-title":"Cell"},{"key":"ref25","article-title":"The atopic eczema\/dermatitis syndrome. Epidemiology, natural course, and immunology of the IgE-associated (\u201cextrinsic\u201d) and the nonallergic (\u201cintrinsic\u201d) AEDs","volume":"13","author":"W\u00fcthrich B","year":"2003","unstructured":"W\u00fcthrich B, Schmid-Grendelmeier P. The atopic eczema\/dermatitis syndrome. Epidemiology, natural course, and immunology of the IgE-associated (\u201cextrinsic\u201d) and the nonallergic (\u201cintrinsic\u201d) AEDs. J Investig Allergol Clin Immunol. 2003, 13:1-5.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3219","article-title":"Dupilumab versus cyclosporine for the treatment of moderate-to-severe atopic dermatitis in adults: indirect comparison using the eczema Area and Severity Index","volume":"99","author":"Ari\u00ebns LF","year":"2019","unstructured":"Ari\u00ebns LF, Gadkari A, van Os-Medendorp H, et al.. Dupilumab versus cyclosporine for the treatment of moderate-to-severe atopic dermatitis in adults: indirect comparison using the eczema Area and Severity Index. Acta Derm Venereol. 2019, 99:851-7. 10.2340\/00015555-3219","journal-title":"Acta Derm Venereol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13730","article-title":"Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis","volume":"172","author":"van der Schaft J","year":"2015","unstructured":"van der Schaft J, Politiek K, van den Reek JM, et al.. Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis. Br J Dermatol. 2015, 172:1621-7. 10.1111\/bjd.13730","journal-title":"Br J Dermatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and safety of Abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Silverberg JI","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, et al.. Efficacy and safety of Abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020, 156:863-73. 10.1001\/jamadermatol.2020.1406","journal-title":"JAMA Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/373389-clinical-assessment-of-abrocitinib-tofacitinib-and-cyclosporine-in-adult-patients-with-moderate-to-severe-atopic-dermatitis-a-retrospective-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T07:37:42Z","timestamp":1749195462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/373389-clinical-assessment-of-abrocitinib-tofacitinib-and-cyclosporine-in-adult-patients-with-moderate-to-severe-atopic-dermatitis-a-retrospective-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.85448","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,6]]}}}